Healthcare Global Enterprises (HCG) has officially been on a significant capital-raising campaign by issuing a rights issue of ₹424.68 crore. This is a strategic initiative to grow the company financially in a huge way. It will help the company to expand its large network of cancer care all over India.
After a majority acquisition by the global investment firm KKR early in 2025, HCG is currently working on a post-acquisition plan that is ambitious and is supposed to reinforce its leading role on the market within the sphere of oncology and meet the new demands of patients in the specialized health market.
Primary objective and infrastructure
The primary objective of this large-scale capital injection is to maintain the growth rate of HCG under the ownership of its new owners. The proceeds of the rights issue are allocated to various important corporate uses.
A large share of the proceeds shall be employed to expand the HCG cancer care facility and adopt new technologies in its programs. The capital will be used to decrease the current debt and increase the working capital of the company.
The company has outlined plans to use ₹170.00 crore for the pre-payment or repayment of outstanding borrowings for itself and its subsidiary, HCG NCHRI Oncology LLP. ₹154.04 crore is set to be used to buy an extra 34% of the check in Vizag Hospital and Cancer Research Center Private Limited, with the rest of the ₹95.57 crore to be spent on general corporate purposes.
Market leadership and rights issue terms
The rights issue is designed to provide current qualified shareholders with a chance to invest in the development of the business by purchasing new shares. HCG is offering a total of 8,294,566 new equity shares at an issue price of ₹512 per share, which includes a face value of ₹10 and a premium of ₹502 per share. This entitlement ratio stands at 1 new rights equity share to 17 fully paid-up equity shares of investors as of the record date, which was March 2, 2026.
This approach enables existing investors to sustain or even expand their ownership of the company, as well as to provide HCG the funds it needs to pursue its growth goals without necessarily depending on debt only. The issue was opened to subscription on March 11, 2026, and closed on March 25, 2026, getting an unsuspected response, a subscription rate of 129.01%.
HCG continues to be the largest dedicated cancer care organization in India with 21 dedicated cancer centers and several multispecialty units. The Indian oncology market is estimated to expand by 20% per year till 2030, which actually constitutes a major opportunity for the established leaders such as HCG. With this capital on board, HCG is well-positioned to take advantage of the rapid growth of specialized healthcare services in India.
The company will always work to ensure that its mission is to provide a wide range of cancer treatments, including, but not limited to, high-precision diagnosis and individualized treatment plans. HCG is incorporating modern technologies with institutional support of KKR and advice of companies such as Cyril Amarchand Mangaldas to enhance the ability to serve the rising demand for state-of-the-art cancer treatment.
Conclusion
The ₹424.68 crore rights issue that HCG successfully launched and oversubscribed is another major milestone in the path that the company is taking to improve the healthcare situation in India. The strategic investment of these funds through debt relief, infrastructure development, and technology campaigns is strengthening the HCG’s resolve to deliver quality and affordable oncology services.
This increased capital will not only enhance the balance sheet of this company but also portray high investor confidence in its long-term vision and business competencies. With the oncology industry in India still in a developmental phase, the improved financial backbone will enable HCG to stay on top of medical innovation and patient-focused care.
Read the full article here